Unblinding and the placebo effect GLP-1RAs come with telltale side effects: nausea, vomiting, and -of course!- weight loss
GLP-1 microdosing aligns with this philosophy by: Shifting from Reactive to Proactive Care Instead of waiting for full-blown diabetes or obesity to develop, microdosing allows us to intervene upstream, potentially preventing disease progression before it fully takes hold
The side effect profiles differ between semaglutide and tirzepatide , and these differences extend to the benefit profiles as well
GLP1 medications, originally for Type 2 diabetes, are now widely used for obesity
L-cysteine can be provided efficiently with N-Acetylcysteine (NAC)
The honest answer is the same: employer opt-in is the deciding variable